SEC Form 4 · accession 0001209191-16-153401
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ron Cohen
Officer — President and CEO · Director
Period of report
Dec 1, 2016
Accepted (ET)
Dec 5, 2016 · 5:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Dec 1, 2016 | S | 7,160 | $20.7377 | D | 479,688 | D | |
| Common StockF3,F4 | holding | — | — | — | 42,940 | I | Beneficial Ownership in Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.30 to $21.25 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F357,060 shares of Acorda Therapeutics, Inc.'s Common Stock that were distributed to the reporting person on September 8, 2016 by the reporting person's grantor retained annuity trust ("GRAT") are included in the shares reported as held directly by the reporting person. These shares were previously reported as held indirectly through the GRAT.
- F4These shares are held in the GRAT, which was established by the reporting person and of which he is the sole trustee.